Literature DB >> 2427841

A randomized double-blind study of atenolol and celiprolol in mild to moderate hypertension.

B Silke, F Rosenthal, S Taylor.   

Abstract

The antihypertensive effects of equivalent beta-blocking doses of atenolol and celiprolol were compared in 55 patients with mild to moderate hypertension. Patients with diastolic blood pressure between 95 and 114 mm Hg were randomized to celiprolol or atenolol once daily. The dose of each agent was titrated from 50 to 100 mg atenolol or from 200 to 400 mg celiprolol if the supine diastolic blood pressure remained greater than 90 mm Hg after 2 to 4 weeks treatment at 24 h following dosing. Following titration patients were maintained at constant dosage for 12 weeks. The average reductions in blood pressure over the period of double-blind therapy were similar; for atenolol -17/-16 mm Hg and for celiprolol -14/-13 mm Hg. Therapeutic success rate (percentage of patients with diastolic blood pressure less than 90 mm Hg or reduction in diastolic blood pressure greater than 10 mm Hg), based on the mean over the maintenance period, was 71% and 59%, respectively. Adverse events were minor and similar for both therapies. Once daily atenolol and celiprolol appeared similar in efficacy and safety in mild to moderate hypertension.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427841     DOI: 10.1097/00005344-198608004-00028

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

Review 1.  Exercise metabolism and beta-blocker therapy. An update.

Authors:  A Head
Journal:  Sports Med       Date:  1999-02       Impact factor: 11.136

Review 2.  Newer beta blockers and the treatment of hypertension.

Authors:  D McAreavey; R Vermeulen; J I Robertson
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 3.  Efficacy of celiprolol in hypertension and angina pectoris. Introduction.

Authors:  R J Norris
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

Review 4.  Progress in antihypertensive therapy with a multiple-action drug.

Authors:  B N Prichard; B Tomlinson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 5.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

6.  Comparison of the antihypertensive effects of celiprolol and acebutolol.

Authors:  D Terziivanov; V Vlahov; N Belovezhdov; Z Gerova
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 7.  Evaluation of celiprolol, a new cardioselective beta 1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly.

Authors:  K D Lamon
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

8.  A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.

Authors:  R J Milne; S Vander Hoorn; R T Jackson
Journal:  Pharmacoeconomics       Date:  1997-09       Impact factor: 4.981

Review 9.  Celiprolol. An evaluation of its pharmacological properties and clinical efficacy in the management of hypertension and angina pectoris.

Authors:  C J Dunn; C M Spencer
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

Review 10.  Celiprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in hypertension and angina pectoris.

Authors:  J G Riddell; R G Shanks; R N Brogden
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.